WA
BMRN icon

Waverly Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waverly Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Buy
6,676
+1,617
+32% +$94.3K ﹤0.01% 1212
2025
Q4 		$301K Sell
5,059
-126
-2% -$6.86K ﹤0.01% 1202
2025
Q3 		$281K Buy
+5,185
New +$297K ﹤0.01% 1067
2014
Q1 		– Sell
-46
Closed -$3K – 700
2013
Q4 		$3K Buy
+46
New +$3.12K ﹤0.01% 735

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Waverly Advisors's BMRN Position: Q1 2026 in Review

Waverly Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 32% in Q1 2026, buying an estimated $94.3K and bringing the position to 6,676 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #1212.

Waverly Advisors first reported a position in BMRN in Q4 2013 and has held it in 4 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Waverly Advisors held 6,676 shares of BioMarin Pharmaceuticals worth $377K as of Q1 2026.
  • Waverly Advisors bought 1,617 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $94.3K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Waverly Advisors's portfolio in Q1 2026, its #1212 holding.
  • Waverly Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 4 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.